Products for Research Use Only

PF-04217903

CAT: 0804-HY-12017-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-12017-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
PF-04217903 is a potent ATP-competitive c-Met kinase inhibitor with Ki of 4.8 nM for human c-Met. PF-04217903 shows more than 1,000-fold selectivity relative to 208 kinases. Antiangiogenic properties[1][2].
CAS Number
956905-27-4
UNSPSC
12352005
Hazard Statement
H302, H315, H320, H335
Target
C-Met/HGFR
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/PF-04217903.html
Purity
99.85
Solubility
DMSO : 20 mg/mL (ultrasonic) |Ethanol : < 1 mg/mL (ultrasonic)
Smiles
OCCN1N=CC(C2=NC3=C(N=C2)N=NN3CC4=CC5=CC=CN=C5C=C4)=C1
Molecular Formula
C19H16N8O
Molecular Weight
372.38
Precautions
H302, H315, H320, H335
References & Citations
[1]Timofeevski SL, et al. Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors. Biochemistry, 2009, 48 (23), 5339-5349.|[2]Zou HY, et al. Sensitivity of selected human tumor models to PF-04217903, a novel selective c-Met kinase inhibitor. Mol Cancer Ther. 2012 Apr;11 (4) :1036-47.|[3]Cui JJ, et al. Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2- (4- (1- (quinolin-6-ylmethyl) -1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl) -1H-pyrazol-1-yl) ethanol (PF-04217903) for the treatment of cancer. J Med Chem. 2012 Sep 27;55 (18) :8091-109.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1

Alternative Products

Popular Products